Topical ruxolitinib: A new treatment for vitiligo [PDF]
, 2023 Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting. The efficacy of the available therapies, including topical corticosteroids and topical calcineurin inhibitors, has historically been limited and the ...
Alberti‐Violetti, S. +10 more
core +4 more sources
Advances in the use of Ruxolitinib in the treatment of vitiligo disease [PDF]
, 2023 Introduction: Vitiligo is an acquired autoimmune hypomelanosis, associated with a genetic component, whose expression is usually triggered by environmental factors. Its typical symptoms are hypopigmented or apigmented macules with a progressive behavior,
González-Argote, Javier +1 more
core +2 more sources
Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]
, 2019 Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran +2 more
core +1 more source
Alopecia areata: a multifactorial autoimmune condition [PDF]
, 2019 Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P. +3 more
core +1 more source
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis [PDF]
, 2022 Topical agents that are currently available for the treatment of atopic dermatitis may represent a valid approach in the management of mild or mild–moderate cases, whereas they are often supplemented with systemic therapies for handling more complex or ...
Calabrese L. +4 more
core +1 more source
287 Effects of ruxolitinib cream on pruritus in black patients with atopic dermatitis [PDF]
, 2022 Atopic dermatitis (AD) is an inflammatory skin disease that has phenotypic differences across race and can be more severe in Black patients. In two phase 3 identical design studies (TRuE-AD1/TRuE-AD2), patients (≥12 years old with AD for ≥2 years ...
Brar, K. K +8 more
core +1 more source
34587 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by anatomic region: Pooled analysis from two randomized phase 3 studies [PDF]
, 2022 Atopic dermatitis (AD) is a highly pruritic inflammatory skin disease. Two phase 3 studies (TRuE-AD1/TRuE-AD2) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator’s Global Assessment (IGA) score of 2/3, and 3%–20% affected body surface
Bissonnette, Robert +2 more
core +1 more source
Successful treatment of palmoplantar pustulosis with topical ruxolitinib. [PDF]
J Dtsch Dermatol GesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 12, Page 1591-1593, December 2025.
Cramer N +3 more
europepmc +2 more sources
Vitiligo: Current Therapies and Future Treatments
Dermatology Practical & Conceptual, 2023 The current management of vitiligo remains challenging; however, different strategies can be proposed to patients with a good efficacy in many cases. First, it is important to identify patients in the active phase of the disease because treatment should
Julien Seneschal, Katia Boniface
doaj +1 more source
34794 Long-term safety and disease control of ruxolitinib cream among Black or African American patients with atopic dermatitis: Pooled results from 2 phase 3 studies [PDF]
, 2022 Atopic dermatitis (AD) is an inflammatory skin disease with a prevalence in the United States of approximately 20%/5%–10% in Black or African American children/adults. In 2 phase 3 studies (TRuE-AD1/TRuE-AD2), 1249 patients (≥12 years old, Investigator’s
Brar, Kanwaljit K +5 more
core +1 more source